Cited by 110Cancer Cells and MetastasisTGF-β signaling in diseasesPancreatic and Hepatic Oncology Research

Determinants and functions of CAFs secretome during cancer progression and therapy

Open access
Linares, Jenniffer, Marín-Jiménez, Juan A., Badia-Ramentol, Jordi, Calon, Alexandre·2021·Frontiers in Cell and Developmental Biology

Abstract

Multiple lines of evidence are indicating that cancer development and malignant progression are not exclusively epithelial cancer cell-autonomous processes but may also depend on crosstalk with the surrounding tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) are abundantly represented in the TME and are continuously interacting with cancer cells. CAFs are regulating key mechanisms during progression to metastasis and response to treatment by enhancing cancer cells survival and aggressiveness. The latest advances in CAFs biology are pointing to CAFs-secreted factors as druggable targets and companion tools for cancer diagnosis and prognosis. Especially, extensive research conducted in the recent years has underscored the potential of several cytokines as actionable biomarkers that are currently evaluated in the clinical setting. In this review, we explore the current understanding of CAFs secretome determinants and functions to discuss their clinical implication in oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcell.2020.621070

Cites

244 of 244 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The prevalent stromal contingent in CMS4 colorectal cancer is likely to contribute to resistance mechanisms.

    “In terms of TME contexture, the prevalent stromal contingent is likely to contribute to resistance mechanisms, for instance through ECM deposition and cancer cells insulation (54), co-migration with cancer cells to metastatic sites (70), chemotherapy-induced secretome fostering metastasis, angiogenesis, immune evasion and/or drug resistance (71), or even drug retention, as demonstrated in the case”
  • Stromal contribution to resistance in CMS4 colorectal cancer occurs through chemotherapy-induced secretome fostering metastasis, angiogenesis, immune evasion and/or drug resistance.

    “chemotherapy-induced secretome fostering metastasis, angiogenesis, immune evasion and/or drug resistance (71)”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A.
Affiliations
Hospital Del Mar (ES)
Corresponding author
Calon, Alexandre
Venue
Frontiers in Cell and Developmental Biology
Published
2021-01-22
Volume
8
Pages
621070-621070
ISSN
2296-634X (ISSN-L)
OpenAlex
W3121447922
Cited by
110
References
244
Citations by year
2026: 13 · 2025: 21 · 2024: 26 · 2023: 21 · 2022: 18 · 2021: 11
FWCI
2.30
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Cell and Developmental Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, other-oa)
Funders
Instituto de Salud Carlos III (CP16/00151, PI17/00211)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
cancer-associated fibroblasts, tumor microenvironment, tumor progression, metastasis, cancer therapy response, cytokines, biomarkers, druggable targets, cancer diagnosis and prognosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review